Reported Saturday, Merck's KEYTRUDA Plus Trastuzumab and Chemotherapy Extends Survival In Advanced Gastric Cancer Or GEJ Adenocarcinoma
Reported Saturday, Merck's KEYTRUDA Plus Trastuzumab and Chemotherapy Extends Survival In Advanced Gastric Cancer Or GEJ Adenocarcinoma
據週六報道，默沙東的KEYTRUDA合併曲妥珠單抗和化療能夠延長晚期胃癌或食管胃連接部腺癌的生存期。
- KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically significant improvement in OS in this patient population
- Results from the final analysis of KEYNOTE-811 are being presented during a Proffered Paper Session at the European Society for Medical Oncology (ESMO) Congress 2024 and published simultaneously in the New England Journal of Medicine
- In the U.S., KEYTRUDA, in combination with trastuzumab and chemotherapy, is indicated under accelerated approval for first-line treatment in the subset of this patient population whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1), based on prior KEYNOTE-811 results
- Keytruda是第一個與曲妥珠單抗和化療聯合應用，在該患者人群中顯示出在總生存期方面有顯著改善的抗PD-1/L1療法。
- KEYNOTE-811的最終分析結果將在2024年歐洲醫學腫瘤學會（ESMO）大會期間的一場推選論文專題會上進行介紹，並同時發表在《新英格蘭醫學雜誌》上。
- 在美國，Keytruda與曲妥珠單抗和化療聯合應用，根據之前的KEYNOTE-811研究結果，已獲得加速批准，用於首線治療該患者人群中表達PD-L1（綜合陽性分數（CPS）≥1）的腫瘤。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。